The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Early-onset breast cancer now accounts for over one-fifth of all breast cancer cases in Victoria, with 1,067 diagnoses out of 5,197 breast cancer ...

BRAF V600E-mutant metastatic colorectal cancer (CRC) was associated with poor clinical outcomes in patients receiving ...